Genzyme Corporation (NASDAQ: GENZ) is getting closer to capitulating to the offer to be acquired by Sanofi-Aventis (NYSE: SNY). At issue this morning is that Genzyme has agreed to open its books to Sanofi-Aventis. …
Friday was a sea of red in the markets, but earnings season creates many winners and losers. This last week brought on another interesting aspect: Many Stocks Got Hammered! It was no easy task…
We always look for standout research calls. The goal is not to just find bullish calls, but calls which have a longer duration of a single trading session or even a single week. The…
Epocrates, Inc. (NASDAQ: EPOC) is closer to its IPO. The company offers mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry. The terms have been set for its 5.36…
For the first nine months of its 2010 fiscal year, E.I. du Pont de Nemours and Co. (NYSE: DD) got nearly one-third of its sales from its agricultural and nutrition division. That’s more than…
Health Affairs Magazine reports that health care costs reached 17.6% of GDP in 2009. The figure rose from 16.6% in 2008. The magazine reported that “The growth rate of health spending continued to outpace…
2010 is ending and 2011 is about to begin. It has been a very interesting year for major biotech stocks, albeit with lower rewards than seen in 2009 as there have been far fewer…
Pfizer’s (NYSE: PFE) CEO Jeff Kindler resigned because he was tired, he says. “The combination of meeting the requirements of our many stakeholders around the world and the 24/7 nature of my responsibilities, has…
Sequenom, Inc. (NASDAQ: SQNM) became a very painful stock for many investors after the problems surfaced over its test results. While things have recovered substantially at the company, pressure has renewed on management now…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is proving why it is one of the top ten stocks to own for the next decade. The company has authorized the repurchase of up to $1 billion…
2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009. In 2009, companies like Jazz Pharmaceuticals, Inc. (NASDAQ:…
Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally. It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful resolution…
GSK agreed to pay $750 million to settle false claims suit over the distribution of some of its drugs. The press statement by the company makes it appear almost as it nothing had happened:…
General Electric Company (NYSE: GE) is still doing M&A deals. The company has had its checkbook out lately and announcing ventures, and this morning came word from GE Healthcare that it was acquiring Clarient,…
The elderly are different than you and me, and it is not just because they are over 65. The habits of older Americans are, in many cases, much different from younger Americans. Older Americans…